89bio Inc (ETNB) Stock Analysis

89bio Inc (ETNB) is a publicly traded company in the HEALTHCARE sector. It trades at $14.84. This page summarizes the public market data, fundamentals, and frequently asked questions for ETNB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $14.84

About 89bio Inc

89bio, Inc. (ETNB) is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, specializing in the development of innovative therapies for liver and cardiometabolic diseases. The company focuses on addressing critical unmet medical needs through a promising pipeline of therapies that aim to enhance patient outcomes and overall quality of life. With a strong commitment to research and development, 89bio is strategically positioned to significantly contribute to ad...

GNG Research Analysis

GNG Research scores 89bio Inc (ETNB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ETNB.

Frequently Asked Questions

Does ETNB pay dividends?

89bio Inc (ETNB) does not currently pay a regular dividend.